Is immunoengineering the key to ensuring that cell therapies can treat disease?
Medicine by Design-funded foundational technology grows into biotech success story: Notch Therapeutics closes an $85 million Series A financing
Medicine by Design-funded research program that aims to generate next-generation immunomodulation therapies has seeded a Canadian biotechnology success story with the closing of an $85-million (U.S.) Series A financing.
Medicine by Design is expanding its regenerative medicine research portfolio with the addition of four multi-disciplinary, multi-institution projects. “These team projects build on Medicine by Design’s successes over its first three years and will strengthen the University of Toronto and its affiliated hospitals as a global centre for regenerative medicine,” said Michael Sefton, executive director of Medicine by Design.